Literature DB >> 19211271

Atrial expression of endothelial nitric oxide synthase in patients with and without atrial fibrillation.

Alicja Bukowska1, Christoph Röcken, Michaela Erxleben, Friedrich-Wilhelm Röhl, Matthias Hammwöhner, Christof Huth, Matthias P A Ebert, Uwe Lendeckel, Andreas Goette.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is associated with oxidative stress within the fibrillating atrial myocardium. Experimental studies suggest that reduced levels of nitric oxide (NO) caused by down-regulation of the NO synthase (eNOS) contribute to the development of prothrombotic endocardial remodeling in AF. This study was designed to determine the endocardial expression of eNOS in atrial tissue samples from patients with and without AF.
METHODS: Tissue microarrays were used to analyze right atrial tissue specimens obtained from 234 patients (38 with AF; 196 with sinus rhythm) for differences in atrial eNOS expression. In selected patients, immunohistological results were confirmed by Western blotting.
RESULTS: Immunohistochemical analyses showed that eNOS is expressed by endocardial cells and myocytes. However, endocardial expression of eNOS was not independently related to AF per se. There was no difference between paroxysmal and persistent AF. Clinical factors like gender (P=.05) and coronary artery disease (P=.06) were associated with down-regulation of eNOS. Interestingly, diabetes mellitus (P=.02) was associated with an up-regulation of endocardial eNOS, whereas other risk factors for thromboembolic events did not influence eNOS levels. Multivariable analysis showed that eNOS expression is influenced by interactions between diabetes mellitus and AF (P=.09) as well as by interactions between gender and AF (P=.04). Lowest levels of eNOS were found in women with AF.
CONCLUSION: AF does not independently effect atrial eNOS expression in humans. Due to the nonuniform regulation of endocardial eNOS expression, it appears unlikely that down-regulation of eNOS is a final common pathway for the development of prothrombotic endocardial remodeling, since classical risk factors for thromboembolic events do not reduce endocardial eNOS protein. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211271     DOI: 10.1016/j.carpath.2008.12.014

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  10 in total

Review 1.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 2.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

3.  Under-recognized post-stroke acute kidney injury: risk factors and relevance for stroke outcome of a frequent comorbidity.

Authors:  Fabrizio Grosjean; Michela Tonani; Rosario Maccarrone; Carlo Cerra; Federica Spaltini; Annalisa De Silvestri; Francesco Falaschi; Simona Migliazza; Carmine Tinelli; Teresa Rampino; Antonio Di Sabatino; Alessandra Martignoni
Journal:  Int Urol Nephrol       Date:  2019-06-20       Impact factor: 2.370

Review 4.  Left Atrial Cardiomyopathy - A Challenging Diagnosis.

Authors:  Fabienne Kreimer; Michael Gotzmann
Journal:  Front Cardiovasc Med       Date:  2022-06-30

Review 5.  The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox.

Authors:  Demetrios Moris; Michael Spartalis; Eleftherios Spartalis; Georgia-Sofia Karachaliou; Georgios I Karaolanis; Gerasimos Tsourouflis; Diamantis I Tsilimigras; Eleni Tzatzaki; Stamatios Theocharis
Journal:  Ann Transl Med       Date:  2017-08

6.  EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  J Arrhythm       Date:  2016-07-11

Review 7.  Atrial Cardiomyopathy: Pathophysiology and Clinical Consequences.

Authors:  Andreas Goette; Uwe Lendeckel
Journal:  Cells       Date:  2021-09-30       Impact factor: 6.600

Review 8.  Hypertension and Arrhythmias: A Clinical Overview of the Pathophysiology-Driven Management of Cardiac Arrhythmias in Hypertensive Patients.

Authors:  Jacopo Marazzato; Federico Blasi; Michele Golino; Paolo Verdecchia; Fabio Angeli; Roberto De Ponti
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-06

Review 9.  Normal and abnormal development of the aortic valve and ascending aortic wall: a comprehensive overview of the embryology and pathology of the bicuspid aortic valve.

Authors:  Nimrat Grewal; Adriana C Gittenberger-de Groot; Jan H Lindeman; Arthur Klautz; Antoine Driessen; Robert J M Klautz; Robert E Poelmann
Journal:  Ann Cardiothorac Surg       Date:  2022-07

10.  Normal and abnormal development of the aortic wall and valve: correlation with clinical entities.

Authors:  N Grewal; M C DeRuiter; M R M Jongbloed; M J Goumans; R J M Klautz; R E Poelmann; A C Gittenberger-de Groot
Journal:  Neth Heart J       Date:  2014-09       Impact factor: 2.380

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.